Finally, they found that GM-CSF deficient CAR-T cells upheld normal activity and had a superior anti-tumor function in vivo leading to an improved overall survival rate in comparison to the conventional anti-CD19 CAR-T cell [116]. The gene discussed is CD19; the disease is neoplasm.